Technology
Health
Biotechnology

Infinity Pharmaceuticals

$1.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-2.05%) Today
-$0.08 (-5.59%) After Hours

Why Robinhood?

You can buy or sell INFI and other stocks, options, ETFs, and crypto commission-free!

About

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. Read More The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Employees
25
Headquarters
Cambridge, Massachusetts
Founded
1995
Market Cap
83.11M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
392.36K
High Today
$1.47
Low Today
$1.42
Open Price
$1.46
Volume
51.25K
52 Week High
$2.92
52 Week Low
$1.00

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
Pharmaceutical
US
North America

News

Yahoo FinanceMay 10

Edited Transcript of INFI earnings conference call or presentation 7-May-19 8:30pm GMT

Q1 2019 Infinity Pharmaceuticals Inc Earnings Call Cambridge May 10, 2019 (Thomson StreetEvents) -- Edited Transcript of Infinity Pharmaceuticals Inc earnings conference call or presentation Tuesday, May 7, 2019 at 8:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Adelene Q. Perkins Infinity Pharmaceuticals, Inc. - Chairman &...

33
NasdaqMay 8

Infinity (INFI) Earnings and Sales Miss Estimates in Q1

Infinity Pharmaceuticals Inc. INFI reported a loss of 24 cents in the first quarter of 2019, wider than a loss of 18 cents in the year-ago quarter. Loss was also wider than the Zacks Consensus Estimate of a loss of 5 cents. Revenues in the first quarter were $2.1 million, which mainly relates to the achievement of a $2-million milestone from PellePharm for the initiation of a phase III study, investigating patidegib (a hedgehog pathway inhibitor) in patients with Gorlin Syndrome. The company did not realiz...

31
NasdaqMay 7

Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Lags Revenue Estimates

14

Earnings

-$0.25
-$0.09
$0.07
$0.23
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.